Fatty liver is the most common chronic liver condition in the United States, and most people who have it have no idea. There is no pain, no jaundice, no yellowing — just a mildly elevated liver enzyme on a routine panel, or a casual mention of 'a little fat on the liver' after an ultrasound ordered for something else. That quiet presentation is exactly the problem. Caught early, fatty liver is reversible. Caught late, it is cirrhosis.
A New Name for an Old Problem
In 2023, the major hepatology societies replaced 'nonalcoholic fatty liver disease' (NAFLD) with MASLD — metabolic dysfunction-associated steatotic liver disease. The more aggressive inflammatory form, previously NASH, is now MASH. The change reflects what we have learned: this condition is not defined by what it is not (nonalcoholic) but by what drives it — metabolic dysfunction. The American Liver Foundation's summary of the MASLD/MASH name change is a useful primer, and the NIDDK's patient overview covers the clinical picture in detail.
How Common Is This, Really
- Roughly 1 in 3 American adults meet criteria for MASLD
- Prevalence climbs to ~70% in people with type 2 diabetes
- ~20-30% of people with simple steatosis progress to MASH
- MASH is now a leading reason for liver transplant in the U.S.
The Disease Spectrum
MASLD is not one thing — it is a progression:
- Simple steatosis — fat in liver cells, no inflammation. Often reversible.
- MASH — fat plus inflammation and liver-cell injury. Scar tissue begins.
- Fibrosis — scarring that progresses through stages F1 through F3.
- Cirrhosis (F4) — extensive scarring, irreversible architectural change.
- Hepatocellular carcinoma — liver cancer, which can arise from cirrhosis and, less commonly, from MASH without cirrhosis.
Our patient pages on fatty liver disease and cirrhosis go deeper into each stage.
Who Should Be Screened
If any of the following apply to you, screening is reasonable:
- Type 2 diabetes or prediabetes — see our pages on diabetes mellitus and impaired fasting glucose
- BMI ≥ 30, or ≥ 27 with central obesity
- Metabolic syndrome — high triglycerides, low HDL, hypertension, elevated waist circumference
- Elevated ALT or AST on any prior lab, even mildly
- High LDL or mixed dyslipidemia — our page on hypercholesterolemia covers this
- Family history of advanced liver disease
What the Blood Work Actually Tells Us
A normal ALT does not rule out MASLD, and an elevated one does not diagnose it. We start with a panel and build a risk picture. Our guide to understanding your blood work explains each liver enzyme in detail.
The FIB-4 score
The most useful noninvasive first-line tool is the FIB-4 index, a simple calculation from four values you already have:
- Age
- AST
- ALT
- Platelet count
Interpretation (adults under 65):
- FIB-4 < 1.3 — low risk of advanced fibrosis; reassess in 2-3 years
- FIB-4 1.3 - 2.67 — indeterminate; proceed to elastography
- FIB-4 > 2.67 — high risk; refer to hepatology
Elastography (FibroScan)
A painless 10-minute ultrasound-based test that measures liver stiffness (a proxy for fibrosis) and fat content. It is now widely available and is the preferred second-line test in most patients with indeterminate FIB-4 scores.
Liver biopsy remains the gold standard but is reserved for cases where noninvasive testing is inconclusive or a competing diagnosis is suspected. The American Association for the Study of Liver Diseases patient resources has excellent guidance on staging.
Reversing MASLD: What Actually Works
Weight loss — the most powerful intervention
The numbers are specific and worth memorizing:
- 3-5% weight loss reduces liver fat (steatosis)
- 7-10% weight loss reduces inflammation and can reverse MASH
- ≥ 10% weight loss can regress some fibrosis
That means a 200-pound adult targeting 180 pounds is aiming at a real, measurable liver outcome, not just a smaller waist.
Diet
A Mediterranean pattern has the strongest evidence — high in vegetables, legumes, whole grains, olive oil, nuts, and fish; low in processed foods, refined carbs, and sugar-sweetened beverages. Our Mediterranean diet heart-healthy eating plan is a practical starting point. Fructose, especially from sugary drinks, is particularly bad for the liver.
Coffee
Multiple studies show that 2-3 cups of coffee daily is associated with reduced liver fibrosis progression. This is one of the few cases where 'more coffee' is legitimate medical advice — black or with minimal sweetener.
Alcohol
Even 'moderate' alcohol accelerates MASLD progression. Our article on how alcohol affects the body after 50 covers why the liver is less forgiving with age. For established MASLD, we generally recommend minimizing alcohol, and for MASH or fibrosis, abstinence.
Medications
- GLP-1 receptor agonists like semaglutide produce meaningful weight loss and improve liver histology
- Resmetirom (Rezdiffra), approved in 2024, is the first drug specifically for MASH with moderate-to-advanced fibrosis
- Pioglitazone helps in selected patients with diabetes and MASH
- Aggressive treatment of diabetes and LDL cholesterol is critical — statins are not contraindicated in MASLD
When Hepatology Gets Involved
We refer to hepatology for:
- FIB-4 persistently above 2.67 or elastography showing F3-F4 fibrosis
- Any suggestion of cirrhosis, varices, or liver decompensation
- Uncertain diagnosis (autoimmune, viral, or metabolic overlap)
- Candidacy for resmetirom or clinical trials
Monitoring Cadence
For patients with MASLD and low-risk FIB-4, we typically repeat the liver panel and FIB-4 every 1-2 years and review lifestyle progress at every visit. For F2 or higher fibrosis, we tighten that to every 6-12 months with imaging, and add screening for liver cancer if cirrhosis develops.
Fatty liver is one of the most rewarding conditions in internal medicine because the interventions work — and they work at the same time on your diabetes risk, heart disease risk, and longevity. If your labs have ever mentioned elevated liver enzymes, or if you carry metabolic risk factors, schedule a visit and we will calculate your FIB-4, review your risk, and build a plan you can actually live with.
